Biomedical subjects

V Vovolis

Publications and source records attributed to V Vovolis.

3 recordsLinked to original sources

PubMed2001

Mizolastine in the treatment of seasonal allergic rhinoconjunctivitis: a European clinical experience with 5408 patients managed in daily practice (PANEOS SAR Study).

BACKGROUND: Mizolastine, a potent H1 antihistamine with additional antiallergic properties, is marketed for the treatment of allergic rhinoconjunctivitis and urticaria. The objective was to investigate the safety and effectiveness of mizolastine under conditions of daily practice in patients with seasonal allergic rhinoconjunctivitis (SAR). METHODS: In an open multicenter study, mizolastine 10 mg daily was administered for 14 days during the pollen season. Nasal and ocular symptoms, time to onset of symptom relief, and effect of the drug on diurnal alertness were evaluated. Safety was evaluated on the basis of self-reported adverse events (AE). RESULTS: A total of 5408 patients (36+/-14 years of age, females=57%) with a history of SAR for 8+/-9 years were treated for a mean of 17.1+/-5.0 days. SAR symptoms improved in 93% and decreased by at least 50% in 86% of patients; 78% reported improvement after the first drug intake and 51% from the first hour. Sixty-nine percent considered mizolastine more effective than other antihistamines taken previously. The incidence of AE was low (3.8%). CONCLUSION: The high responder rate, the rapid onset of action, and the low incidence of AE observed in this large multicenter study confirm the previously reported beneficial efficacy and safety of mizolastine in the management of SAR.

Adolescent↗

PubMedDate not supplied

Silk-induced asthma.

The existence of professional allergens in the home environment is important because their avoidance usually resolves the problem completely. We report on a case of an asthmatic woman who, for five years, was helping her husband create large artistic screens with the cocoons of the silkworms. Extensive laboratory evaluation revealed that she was allergic to silk and her symptoms resolved in three months following discontinuation of her exposure to silk allergens.

Adult↗

PubMedDate not supplied

Is month of birth a risk factor for subsequent development of pollen allergy in adults?

A comparison of the date of birth of 1501 adult patients with severe seasonal respiratory allergy (allergic rhinitis or bronchial asthma) due to parietaria, olive, and grass pollens with the expected births within 2,020,420 births in South Greece during the same period, was performed. The relative risk for developing respiratory allergy was characteristically increased in those born in a specific period of time different for each pollen. The relative risk for parietaria was increased (1.47) in those born in March; for olive it was 1.6 for May; 1.2 for April; and 1.4 for March, while the relative risk for grasses was 1.2 in those born in June and July. These findings are indicative of the importance of the month of birth; that is, the early exposure to pollens, for the development of respiratory allergy to certain pollens during adulthood. Because our findings do not directly correlate completely with the aerobiology studies on pollen calculation in Athens' atmosphere, we supposed that other environmental factors, e.g., the local intensity of the first pollination or the influence of weather conditions, may contribute to the final development of respiratory allergy as well. The most impressive finding was the significant influence of the month of birth in the development of respiratory allergy due to parietaria and olive pollens during adulthood.

Adult↗